Hemogenyx Pharmaceuticals’s usbsidiary Hemogenyx-Cell S.A. has reportedly entered into a further collaboration agreement with Orgenesis, – a vertically-integrated biopharmaceutical company with expertise and experience in cell therapy development and manufacturing, to collaborate on the further development of Human Postnatal Hemogenic Endothelial Cell technology, Hu-PHEC which is a cell replacement product candidate to generate cancer-free, patient-matched blood stem cells after transplantation into the patient.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, said:“We are very pleased to announce this further collaboration with Orgenesis to rapidly develop and bring to the market our Hu-PHEC technology. The collaboration is a testiment to the value of our Hu-PHEC based approach to drastically improving bone marrow transplants.“
Vered Caplan, CEO of Orgenesis, said: “We are excited to collaborate with Hemogenyx, as this technology has significant potential to transform bone marrow transplantation and potentially solve the problem of lack of donors. Our goal is to advance the field of cell therapy through using this unique and innovative approach for generation of blood stem cells.“
According to the terms of the agreemnt, Orgenesis and/or one or more qualified investors (“Investors”) will advance to Hemogenyx-Cell a convertible loan in an amount of not less than US$1,000,000 (the “Convertible Loan”).